US EditionHarbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
- Harbour BioMed has acquired common stock in Spruce Biosciences, holding approximately 3.8% of the total outstanding shares.
- The collaboration focuses on advancing SPR202, an anti-corticotropin-releasing hormone monoclonal antibody, for various disorders.
- Dr. Jingsong Wang stated that this marks a significant milestone in their partnership with Spruce Biosciences.
- Harbour BioMed aims to enhance its pipeline through research, strategic collaborations, and acquisitions.
50 Articles
50 Articles
Chatham Star Tribune
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary,…
Harbour BioMed Acquires Common Stock in Spruce Biosciences
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approxima…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
